The New York Times considered how the official end of the GLP-1 shortages is affecting patients — you know, the people who all this is supposed to be about? APC Immediate Past Board Chair Joe Navarra was one of the sources talking about patient concerns, while CEO Scott Brunner provided a one-sentence reality check about the role of pharmacy compounding: “Compounding,” he reminded the Times, “was never intended to compete with the drugmakers.”